Analysts expect Axalta Coating Systems Ltd (NYSE:AXTA) to report $0.24 EPS on April, 27.They anticipate $0.07 EPS change or 41.18% from last quarter’s $0.17 EPS. AXTA’s profit would be $58.40M giving it 32.83 P/E if the $0.24 EPS is correct. After having $0.28 EPS previously, Axalta Coating Systems Ltd’s analysts see -14.29% EPS growth. It is down 8.80% since September 2, 2016 and is uptrending. It has outperformed by 0.67% the S&P500.
Among 6 analysts covering Exelixis (NASDAQ:EXEL), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Exelixis had 8 analyst reports since January 19, 2016 according to SRatingsIntel. The rating was downgraded by Stifel Nicolaus to “Hold” on Tuesday, February 28. The firm earned “Buy” rating on Monday, April 4 by Stifel Nicolaus. The stock of Exelixis, Inc. (NASDAQ:EXEL) has “Outperform” rating given on Tuesday, January 19 by Leerink Swann. The stock has “Overweight” rating by Piper Jaffray on Monday, October 10. On Thursday, September 15 the stock rating was maintained by Stifel Nicolaus with “Buy”. Deutsche Bank initiated the stock with “Buy” rating in Thursday, November 3 report. See Exelixis, Inc. (NASDAQ:EXEL) latest ratings:
31/03/2017 Broker: Needham Rating: Buy New Target: $28.00 Initiates Coverage On
16/03/2017 Broker: Oppenheimer Rating: Perform Initiates Coverage On
28/02/2017 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Hold Old Target: $21 New Target: $22 Downgrade
03/11/2016 Broker: Deutsche Bank Rating: Buy New Target: $17.00 Initiate
Axalta Coating Systems Ltd. is a holding company. The company has market cap of $7.67 billion. The Firm is a manufacturer, marketer and distributor of coatings systems primarily serving the transportation industry. It has a 184.74 P/E ratio. The Company’s divisions include Performance Coatings and Transportation Coatings.
Among 13 analysts covering Axalta Coating Systems (NYSE:AXTA), 9 have Buy rating, 0 Sell and 4 Hold. Therefore 69% are positive. Axalta Coating Systems had 27 analyst reports since September 2, 2015 according to SRatingsIntel. The firm has “Outperform” rating by RBC Capital Markets given on Monday, December 7. Credit Suisse maintained the shares of AXTA in report on Monday, June 27 with “Outperform” rating. The rating was maintained by Barclays Capital with “Equal-Weight” on Friday, September 11. Citigroup maintained it with “Buy” rating and $36 target in Monday, April 18 report. On Thursday, February 9 the stock rating was downgraded by Gabelli to “Hold”. Gabelli initiated it with “Buy” rating and $37.0 target in Thursday, September 1 report. On Tuesday, February 16 the stock rating was upgraded by Jefferies to “Buy”. The firm has “Outperform” rating given on Thursday, February 9 by RBC Capital Markets. The rating was maintained by Deutsche Bank on Friday, October 2 with “Buy”. The stock of Axalta Coating Systems Ltd (NYSE:AXTA) has “Outperform” rating given on Monday, February 8 by RBC Capital Markets.
Since November 9, 2016, it had 0 insider purchases, and 26 sales for $26.04 million activity. 11,000 shares were sold by Senner Christopher J., worth $250,800 on Friday, March 3. FELDBAUM CARL B had sold 10,000 shares worth $217,700 on Monday, March 20. PAPADOPOULOS STELIOS sold 10,000 shares worth $216,600. Another trade for 10,000 shares valued at $213,000 was made by MARCHESI VINCENT T on Monday, April 3. $368,060 worth of stock was sold by Schwab Gisela on Thursday, December 1. 204,894 shares valued at $3.65M were sold by SCANGOS GEORGE A on Monday, December 5. On Monday, March 13 the insider COHEN CHARLES sold $218,200.
Investors sentiment decreased to 1.04 in Q4 2016. Its down 1.03, from 2.07 in 2016Q3. It turned negative, as 21 investors sold Exelixis, Inc. shares while 78 reduced holdings. 40 funds opened positions while 63 raised stakes. 232.36 million shares or 7.60% more from 215.94 million shares in 2016Q3 were reported. Smith Asset Mgmt Group Inc Ltd Partnership owns 29,410 shares. Price T Rowe Associates Md reported 0.03% stake. Strs Ohio stated it has 0% of its portfolio in Exelixis, Inc. (NASDAQ:EXEL). , New York-based fund reported 130,760 shares. Sei accumulated 43,590 shares. Bank & Trust Of Montreal Can owns 231,765 shares or 0% of their US portfolio. Products Prns Ltd reported 0.69% of its portfolio in Exelixis, Inc. (NASDAQ:EXEL). State Board Of Administration Of Florida Retirement System accumulated 149,498 shares. 13,670 are held by Natl Planning. Financial Bank Of America De holds 354,751 shares or 0% of its portfolio. Piermont Capital Management Inc has invested 0.11% in Exelixis, Inc. (NASDAQ:EXEL). Airain reported 0.13% stake. Keybank National Association Oh invested 0% of its portfolio in Exelixis, Inc. (NASDAQ:EXEL). California State Teachers Retirement Systems has 0.01% invested in Exelixis, Inc. (NASDAQ:EXEL). Blackrock Incorporated invested in 0% or 56,709 shares.
Exelixis, Inc. is a biopharmaceutical company. The company has market cap of $5.97 billion. The Firm is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. It currently has negative earnings. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
About 1.24 million shares traded. Exelixis, Inc. (NASDAQ:EXEL) has risen 75.74% since September 2, 2016 and is uptrending. It has outperformed by 67.61% the S&P500.